Tafas v. Dudas et al Doc. 110

Case 1:07-cv-00846-JCC-TRJ Document 110 Filed 12/19/2007 Page 1 of 6

UNITED STATES DISTRICT COURT FOR THE EASTERN DISTRICT OF VIRGINIA Alexandria Division

TRIANTAFYLLOS TAFAS,	
Plaintiff,)
v.) Civil Action No. 1:07cv846 (JCC/TRJ)
JON W. DUDAS, et al.)
Defedants.)
CONSOL	IDATED WITH
SMITHKLINE BEECHAM CORPORATION, et al.,))
Plaintiffs,))
V.	Civil Action No. 1:07cv1008 (JCC/TRJ)
JON W. DUDAS, in his official capacity as, Under-Secretary of Commerce for Intellectual Property and Director of the United States Patent and Trademark Office, <i>et al.</i> ,)))))))))
Defendants.)

MOTION OF AMICUS CURIAE HUMAN GENOME SCIENCES, INC. FOR LEAVE TO FILE ITS BRIEF IN SUPPORT OF THE "GSK" PLAINTIFFS' MOTION FOR SUMMARY JUDGMENT

Human Genome Sciences, Inc. ("HGS"), by undersigned counsel, moves for leave to file its brief as *amicus curiae* in support of plaintiffs Smithkline Beecham Corporation, Smithkline Beecham PLC and Glaxo Group Limited's Motions for Summary Judgment.

HGS is a small biopharmaceutical company dedicated to discovery, development, manufacture and marketing of innovative drug products for patients with unmet medical needs

including lupus, hepatitis C and anthrax. Since its founding in 1992 over 500 patents have been issued to HGS. Currently HGS has more than 200 patent applications pending at the USPTO. Unlike GSK, HGS has not vet introduced any products into the market.

HGS wishes to submit a brief addressing how the retroactive impact of the new Rules will adversely impact small innovative companies like HGS who are trying to maximize their as yet un-recouped capital investment in cutting edge biopharmaceutical innovations by consolidating patent applications.

Pursuant to this Court's Order of December 5, 2007, HGS respectfully requests leave of this Court to file the enclosed *Amicus* Brief explaining the especially dramatic impact the retroactive application of the new rules would have on HGS and similar small biopharmaceutical companies. HGS believes its special situation provides it with a unique perspective that will be useful to the Court in adjudicating the parties' cross motions for summary judgment.

HGS is authorized to state that GSK Plaintiffs and Mr. Tafas have consented to the filing of this brief. Additionally, The United States Patent and Trademark Office takes no position in response to the filing of this brief. Accompanying this Motion is a proposed order granting HGS leave to file the enclosed Amicus Brief.

WHEREFORE, for good cause shown, Human Genome Sciences, Inc. requests that the Court grant leave to file the attached *Amicus* Brief and deem the brief filed as of the date of this motion without need to refile.

Dated: This 19th day of December, 2007. Respectfully Submitted,

Robert E. Scully Jr. VA Bar No. 19218 Counsel for Amicus Curiae Human Genome Sciences, Inc. STITES & HARBISON PLLC

1199 North Fairfax Street, Suite 900 Alexandria, Virginia 22314 (703) 739-4900 Fax: (703) 739-9577 rscully@stites.com

James H. Davis, Ph.D., J.D.

Executive Vice President
General Counsel
Michele M. Wales, Ph.D., J.D.
Vice President of Intellectual Property
Jared S. Cohen, Ph.D., J.D.
Patent Attorney
Human Genome Sciences, Inc.
14200 Shady Grove Road
Rockville, MD 20850

CERTIFICATE OF SERVICE

I hereby certify that on this 19th day of December 2007, the foregoing pleading was filed electronically using the CM/ECF system, which will send notification by electronic means to the following counsel of record:

> Joseph D. Wilson, Esq. Kelley Drye & Warren LLP 3050 K. Street, NW, Suite 400 Washington, D.C. 20007-5108 Email: jwilson@kellevdrye.com

Attorney for Plaintiff in Case No. 1:07cv846

Elizabeth M. Locke, Esq. Kirkland & Ellis LLP 655 15th Street, NW, Suite 1200 Washington, D.C. 20005 Email: elocke@kirkland.com

and

Craig C. Reilly, Esq. Richard McGettigan Reilly & West PC 1725 Duke Street, Suite 600 Alexandria, Virginia 22314 Email: craig.reilly@rmrwlaw.com

Attorneys for Plaintiffs in Case No. 1:07cv1008

Chuck Rosenberg, Esq. United States Attorney Lauren A. Wetzler, Esq. R. Joseph Sher, Esq. Andrew Price, Esq. Assistant United States Attorneys United States Attorney's Office 2100 Jamison Avenue Alexandria, Virginia 22314 Email: lauren.wetzler@usdoj.gov

Attorneys for Defendants in Case Nos. 1:07cv846

and 1:07cv1008

Rebecca Malkin Carr, Esq. Pillsbury Winthrop Shaw Pittman LLP 2300 N. Street, NW Washington, D.C. 20037 Email: Rebecca.carr@pillsburylaw.com

and

Scott J. Pivnick, Esq. Pillsbury Winthrop Shaw Pittman LLP 1650 Tysons Boulevard McLean, Virginia 22102-4856 Email: scott.pivnick@pillsburylaw.com

Attorneys for Amicus Elan Pharmaceuticals, Inc.

James Murphy Dowd, Esq. Wilmer Cutler Pickering Hale & Dorr, LLP 1455 Pennsylvania Avenue, NW Washington, D.C. 20004 Email: james.dowd@wilmerhale.com

Attorney for Amicus Pharmaceutical Research and Manufacturers of America

Dawn-Marie Bey, Esq. Kirkpatrick Stockton LLP 700 13th Street, NW, Suite 800 Washington, D.C. 20005 Email: dbey@kslaw.com

Attorney for Amicus Hexas, LLC, The Roskamp Institute and Tikvah Therapeutics, Inc.

Randall Karl Miller, Esq. Arnold & Porter, LLP 1600 Tysons Boulevard, Suite 900 McLean, Virginia 22102 Email: randall miller@aporter.com

Attorney for Amicus Biotechnology Industry Organization and Amicus Monsanto Company

Charles Gorenstin, Esq. Birch, Stewart, Kolasch and Birch, LLP 8110 Gatehouse Road, Suite 100 East Falls Church, Virginia 22042 email: cg@bskb.com

Attorney for Amicus Intellectual Property Institute Williams Mitchell College of Law

Thomas J. O'Brien, Esq.
Morgan Lewis & Blockius LLP
1111 Pennsylvania Avenue, NW
Washington, D.C. 20004
Email: to'brien@morganlewis.com
Attorney for Amicus American Intellectual
Property Law Association

 $/_{\rm S}/$

rscully@stites.com

Robert E. Scully Jr.
VA Bar No. 19218
Counsel for *Amicus Curiae* Human
Genome Sciences, Inc.
STITES & HARBISON PLLC
1199 North Fairfax Street, Suite 900
Alexandria, Virginia 22314
(703) 739-4900
Fax: (703) 739-9577